Cargando…
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
BACKGROUND: Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinica...
Autores principales: | Gentilcore, Giusy, Madonna, Gabriele, Mozzillo, Nicola, Ribas, Antoni, Cossu, Antonio, Palmieri, Giuseppe, Ascierto, Paolo A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586362/ https://www.ncbi.nlm.nih.gov/pubmed/23317446 http://dx.doi.org/10.1186/1471-2407-13-17 |
Ejemplares similares
-
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a (V600E)BRAF inhibitor): a case report
por: Simeone, Ester, et al.
Publicado: (2012) -
The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012) -
NF-κB as potential target in the treatment of melanoma
por: Madonna, Gabriele, et al.
Publicado: (2012) -
Phenotype characterization of human melanoma cells resistant to dabrafenib
por: Cordaro, Fabiola Gilda, et al.
Publicado: (2017) -
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)